Advertisement

Quality assurance in the treatment of acute renal failure

  • Andre A. Kaplan
Part of the Developments in Nephrology book series (DINE, volume 39)

Abstract

Despite a plethora of information regarding what is or isn’t adequate dialysis prescription for end stage renal failure [1-3] there is an amazing paucity of information regarding what is adequate treatment for acute renal failure. Similarly, quality assessment for the dialytic treatment of relatively stable patients with ESRD can be reasonably distilled down to simple mortality [4], an approach which is not easily applicable to acutely ill patients whose mortality risk is already very high and in whom acute renal failure may be an incidental, supplemental insult. Thus, it is still commonly believed that acutely ill patients die with renal failure and not from renal failure. In agreement with this concept, a recent NIH sponsored conference has suggested that outcome parameters for patients with acute renal failure should be stratified into several levels; by the length of stay, both in the ICU and in the hospital; by the number who recover renal function; by the amount of renal function recovered and, finally, the percentage survival in terms of discharge from the ICU and the hospital [5]. Clearly, considering the initial poor survival of acutely ill patients even before developing ARF, and considering the variability of etiologies and comorbidities, it is exceedingly difficult to obtain such stratified outcome parameters from the experience of a single medical institution. Thus, the same aforementioned NIH conference concluded that evidence based guidelines for the treatment of acute renal failure must be obtained from multicenter trials that use standardized criteria for management and outcomes. Nonetheless, even in the context of a multicenter trial, problems in interpretation of results remain. As convincingly argued by Bellomo and Boyce, the geographical variability in survival rates, the need for large numbers of patients (≤ 160) and the differing expertise of the treating physicians present seemingly insurmountable problems [6].

Keywords

Acute Renal Failure Plasma Exchange Continuous Renal Replacement Therapy Therapeutic Plasma Exchange Urea Clearance 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Gotch F and Sargent JA. A mechanistic analysis of the National Cooperative Dialysis Study. Kidney Int 1985; 28:526–34.PubMedCrossRefGoogle Scholar
  2. 2.
    Owen WF, Lew NL, Liu Y et al. The urea reduction ration and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N Eng J Med 1993; 329:1001–6.CrossRefGoogle Scholar
  3. 3.
    Parker TF, Husni L, Huang W et al. Effects of dose of dialysis on morbidity and mortality. Am J Kidney Dis 1994; 23:670–80.PubMedGoogle Scholar
  4. 4.
    Charra B, Calemard E, Fuffet M et al. Survival as an index of adequacy of dialysis. Kidney Int 1992; 41:1286 91PubMedCrossRefGoogle Scholar
  5. 5.
    DuBose Jr TD, Warnock DG, Mehta RL, Bonventre JV, Hammerman MR, Molitoris BA et al. ARF in the 21st century: recommendations for management and outcomes assessment. Am J Kidney Dis 1997; 29:793–9Google Scholar
  6. 6.
    Bellomo R and Boyce N. Does continuous hemodiafiltration improve survival in acute renal failure. Semin Dial 1993; 6:16–19.Google Scholar
  7. 7.
    Kaplan AA. Extracorporeal blood purification in the treatment of acute renal failure with multiorgan involvement. Blood Purif 1996; 14:86–93PubMedGoogle Scholar
  8. 8.
    Teschan PE, Baxter CR, O’Brien TF, Freyhof JN and Hall WH. Prophylactic hemodialysis in the treatment of acute renal failure. Am J Med 1960; 53:992 1016.Google Scholar
  9. 9.
    Kleinknecht D, Jungers P, Chanard J, Barbanel C and Ganeval DD. Uremic and non-uremic complications in acute renal failure. Kidney Int 1972; 1:190 6.PubMedCrossRefGoogle Scholar
  10. 10.
    Conger JD. A controlled evaluation of prophylactic dialysis in post-traumatic acute renal failure. J Trauma 1975; 15:1056–63.PubMedGoogle Scholar
  11. 11.
    Gillum DM, Dixon BS, Yanover MJ, Kelleher SP, Shapiro MD, Benedetti RG et al. The role of intensive dialysis in acute renal failure. Clin Nephrol 1986; 25:249–55.PubMedGoogle Scholar
  12. 12.
    Storck M, Hartl WH, Zimmerer E and Inthorn D. Comparison of pump-driven and spontaneous haemofiltration in postoperative acute renal failure. Lancet 1991; i:452–5.CrossRefGoogle Scholar
  13. 13.
    Tapolyai M, Fedak S, Chaff C and Paganini EP. Delivered dialysis dose may influence acute renal failure outcome in ICU patients.(abstract) J Am Soc Nephrol 1994; 5:530.Google Scholar
  14. 14.
    Paganini EP, Tapolyai M, Goormastic M, Halstenberg W, Kozlowski L, Leblanc M et al. Establishing a dialysis therapy/patient outcome link in intensive care unit acute dialysis for patients with acute renal failure. Am J Kidney Dis 1996; 28:S81–9.Google Scholar
  15. 15.
    Schiffl H, Lang SM, Konig A and Held E. Dose of intermittent hemodialysis and outcome of acute renal failure: a prospective randomized study, (abstract) J Am Soc Nephrol 1997; 8:290–1.Google Scholar
  16. 16.
    Kaplan AA. Continuous arterio-venous hemofiltration and related therapies. In Jacobs C, Kjellstrand CM, Koch KM, Winchester JF, editors. Replacement of renal function by dialysis, 4th edition. Dordrecht, Kluwer Academic Press, 1996; 390–417.Google Scholar
  17. 17.
    Evanson JA, Ikizler TA, Schulman G, Knights S, Himmelfarb J and Hakim RM. Delivery of intermittent hemodialysis in acute renal failure patients (abstract). J Am Soc Nephrol 1997; 8:282.Google Scholar
  18. 18.
    Leblanc m, Tapolyai M and Paganini EP. What dialysis dose should be provided in acute renal failure? a review. Adv Renal Replace Ther 1995; 2:255–64.Google Scholar
  19. 20.
    Coraim F, Fasol R, Stellwag F and Wolner E. Continuous arteriovenous hemofiltration after cardiac surgery. In Sieberth HG and Mann H, editors. Contributions to nephrology, vol 93. Continuous arteriovenous hemofiltration. Basel, Karger, 1985; 116–24.Google Scholar
  20. 21.
    Coraim F and Wolner E. Management of cardiac surgery patients with continuous arteriovenous hemofiltration. In Sieberth HG and Mann H, editors. Contributions to nephrology, vol 93. Continuous arteriovenous hemofiltration. Basel, Karger, 1985; 103–10.Google Scholar
  21. 22.
    Coraim FJ, Coraim HP, Ebermann R and Stellwag FM. Acute respiratory failure after cardiac surgery: clinical experience with the application of continuous arteriovenous hemofiltration. Crit Care Med 1986; 14:714–8.PubMedCrossRefGoogle Scholar
  22. 23.
    Bellomo R, Tippiong P and Boyce N. Tumor necrosis factor clearances during veno-venous hemodiafiltration in the critically ill. Am Soc Artif Intern Org 1991; 37:M322–23.Google Scholar
  23. 24.
    Cottrell AC and Mehta RL. Cytokine kinetics in septic ARF patients on continuous veno-veno hemodialysis (abstract). J Am Soc Nephrol 1992; 3:279.Google Scholar
  24. 25.
    Gomez A, Wang R, Unruh H, Light RB, Bose D, Chau T et al. Hemofiltration reverses left ventricular dysfunction during sepsis in dogs. Anesthesiology 1990; 73:671–85.PubMedCrossRefGoogle Scholar
  25. 26.
    Stein B, Pfenninger E, Grunert A, Schmitz JE, Deller A and Kocher F. The consequences of continuous hemofiltration on lung mechanics and extravascular lung water in a porcine endotoxic shock model. Int Care Med 1991; 17:293–8.CrossRefGoogle Scholar
  26. 27.
    Grootendorst AF and van Bommel EFH. The role of hemofiltration in the critically-ill intensive care unit patient: present and future. Blood Purif 1993; 11:209–23.PubMedGoogle Scholar
  27. 28.
    Journois D and Silvester W. Continuous hemofiltration in patients with sepsis or multiorgan failure. Semin Dialysis 1996; 9:173–8.Google Scholar
  28. 29.
    Grootendorst AF, Bommel EFH van, Hoven B van der, Leengoed LAMG van and Osta ALM van. High volume hemofiltration improves hemodynamics of endotoxin-induced shock in the pig. J Crit Care 1992; 7:67–72.CrossRefGoogle Scholar
  29. 30.
    Grootendorst AF, van Bommel EFH, van der Hoven B, van Leengoed LAMG and van Osta ALM. High volume hemofiltration improves right ventricular function of endotoxininduced shock in the pig. Int Care Med 1992; 18:235–40.CrossRefGoogle Scholar
  30. 31.
    van Bommel EFH, Grootendorst AF and van Leengoed LAMG. Influence of high-volume hemofiltration on hemodynamics in porcine endotoxic shock (abstract). Blood Purif 1992; 10:88.Google Scholar
  31. 32.
    Grootendorst AF and van Saase JL. The role of continuous renal replacement therapy in sepsis and multiorgan failure. Am J Kidney Dis 1996; 28:S50–7.Google Scholar
  32. 33.
    Riera JASI, Vela JLP, Quintana L, Lopez EA, de Solo BO and Checa AA. Cytokines clearance during venovenous hemofiltration in the trauma patient. Am J Kidney Dis 1997; 30:483–8.Google Scholar
  33. 34.
    Schetz M, Ferdinande P, Van den Berghe G, Verwaest C and Lauwers P. Removal of pro inflammatory cytokines with renal replacment therapy: sense or non-sense? Int Care Med 1995; 21:169–76.CrossRefGoogle Scholar
  34. 35.
    Vallance P and Moncada S. Hyperdynamic circulation in cirrhosis: a role for nitric oxide? Lancet 1991; 337:776–8.PubMedCrossRefGoogle Scholar
  35. 36.
    Parrillo JE. Pathogenetic mechanisms of septic shock. N Eng J Med 1993; 328:1471–7.CrossRefGoogle Scholar
  36. 37.
    Travera Da Silva A, Kaulbach HC, Chuidian FS, Lambert DR, Suffredini AF and Danner RL. Shock and multiple organ dysfunction after self administration of Salmonella endotoxin. N Engl J Med 1993; 328:1457–60.CrossRefGoogle Scholar
  37. 38.
    Osterud B. Meningococcal septicemia: the use of plasmapheresis or blood exchange and how to detect severe endotoxin induced white cell activation. Scand J Clin Lab Invest 1985; 45:47–51.Google Scholar
  38. 39.
    Bjorvatn B, Bjertnaes L, Fadnes HO, Flaegstad T, Gutteberg TJ, Kristiansen BE et al. Meningococcal septicaemia treated with combined plasmapheresis and leucapheresis or with blood exchange. Br Med J 1984; 288:439–41.Google Scholar
  39. 40.
    Brandtzaeg P, Sirnes K, Folsland B, Godal HC, Kierulf P, Bruun JN et al. Plasmapheresis in the treatment of severe meningococcal or pneumococcal septicaemia with DIC and fibrinolysis: preliminary data on eight patients. Scand J Clin Lab Invest 1985; 45:53–5.Google Scholar
  40. 41.
    Brandtzaeg P, Kierulf P, Gaustad P, Skulberg A, Bruun JN, Halvorsen S et al. Plasma endotoxin as a predictor of multiple organ failure and death in systemic meningococcal disease. J Infect Dis 1989; 159:195–204.PubMedGoogle Scholar
  41. 42.
    Westindorp RGJ, Brandt A, Thompson J. Dik H and Meinders AE. Experiences with plasma and leucapheresis in meningococcal septicaemia (abstract). Int Care Med 1990; 16:S102.Google Scholar
  42. 43.
    McClelland P, Williams PS, Yaqoob M, Mostafa SM and Bone JM. Multiple organ failure a role for plasma exchange? Int Care Med 1990; 16:100 3.Google Scholar
  43. 44.
    Drapkin MS, Wisch JS, Gelfand JA, Cannon JG and Dinarello CA. Plasmapheresis for fulminant meningococcemia. Pediatr Infect Dis J 1989; 8:399–400.PubMedCrossRefGoogle Scholar
  44. 45.
    van Deuren M, Santman FW, van Dalen R, Sauerwein RW, Span LFR and van der Meer JWM. Plasma and whole blood exchange in meningococcal sepsis. Clin Infect Dis 1992; 15:424–30.PubMedGoogle Scholar
  45. 46.
    Niklasson PM, Lundbergh P, and Strandeil T. Prognostic factors in meningococcal disease. Scand J Infect Dis 1971; 3:17–25.PubMedGoogle Scholar
  46. 47.
    Stegmayr BG. Plasmapheresis in severe sepsis or septic shock. Blood Purif, 1996; 14:94–101.PubMedCrossRefGoogle Scholar
  47. 48.
    Hanasawa, K, Aoki H, Yoshioka T, Matsuda K, Tani T and Kodama M. Novel mechanical assistance in the treatment of endotoxic and septicemic shock. Am Soc Artif Intern Organs Trans 1989; 35:341–3.Google Scholar
  48. 49.
    Kaplan AA. Therapeutic plasma exchange for non-renal disease. Semin Dialysis 1996; 9:265–75.Google Scholar
  49. 50.
    Hauser W, Christmann FJ, Klein T and Traut G. Therapeutic plasma exchange in septic shock. In Bambauer R, Malchesky PS and Falkenhagen D, editors. Therapeutic plasma exchange and selective plasma separation. Stuttgart-New York, Schattauer, 1987; 287–93.Google Scholar
  50. 51.
    Stegmayr BG. Plasma exchange in patients with septic shock including acute renal failure. Blood Purif 1996; 14:102–8.PubMedGoogle Scholar
  51. 52.
    Barzilay E, Kessler D, Berlot G, Gullo A, Geber D and Zeev IB. Use of extracorporeal supportive techniques as additional treatment for septic induced multiple organ failure patients. Crit Care Med 1989; 17:634–8.PubMedCrossRefGoogle Scholar
  52. 53.
    Kaplan AA. Renal problems in critically ill patients. In Bongard FS and Sue DY, editors. Current diagnosis and treatment in critical care. Lange-Appleton, 1994; 88–116.Google Scholar
  53. 54.
    Maroni BJ, Steinman TI and Mitch WE. A method for estimating nitrogen intake of patients with chronic renal failure. Kidney Int 1985; 27:58–65.PubMedCrossRefGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1999

Authors and Affiliations

  • Andre A. Kaplan

There are no affiliations available

Personalised recommendations